Coronary Stents – Unblocking the Blocked Paths By Current Industry: Boston Scientific Corporation, Abbott, Medtronic plc, B. Braun Melsungen AG, Stentsy SA, Terumo Interventional Systems

Increasing product launches coupled with increasing geographical approval in drug eluting coronary stents is propelling growth of the coronary stents market. For instance, in May 2018, Abbott received the U.S. FDA approval for XIENCE Sierra, the new generation of everolimus-eluting coronary stent. The XIENCE received approval from the Japan’s regulatory body in April 2018, and CE mark from European regulatory bodies in 2017. Furthermore, companies are also evaluating and launching products with novel material, such as with metal like cobalt chromium and fully biodegradable stents.

Get a Request Sample of Research Report @ www.coherentmarketinsights.com/insight/request-sample/2031

For instance, in 2017, Biotronik received FDA approval for PRO-Kinetic energy cobalt chromium-based bare metal coronary stent system to treat coronary artery blockage. However, coronary stents market is also subjected to the factors such as stringent regulatory approval policies for the interventional devices and medical complications such as restenosis and thrombosis, which are expected to restrain coronary stents market growth.

Moreover, technological advancement such as nano-coated coronary stents are propelling its adoption, thus aiding in the market growth. For instance, in 2017, CeloNova BioSciences Inc. is evaluating its proprietary Cobra PzF Nanocoated Coronary Stents (NCS) in patients with high bleeding risk. Nanocoated coronary stents are alternate therapy for patients incompatible to drug eluting stents and long term antiplatelet therapy.

Request for Customization of Research @ https://www.coherentmarketinsights.com/insight/request-customization/2031

According to European Heart Network’s European Cardiovascular Disease Statistics 2017, in 2015, new cases registered with cardiovascular disease in Europe was around 11.3 million with nearly 6.1 million new cases of cardiovascular disease in the European Union. The number is further expected to increase with increase in the rate of obese population.

However, Asia Pacific coronary stents market is expected to witness significant growth due to lower surgical cost in emerging countries such as India and China, which is attracting medical tourist. For instance, countries like Thailand and Malaysia is the most preferred destination for medical tourist, owing to its competitively affordable medical services. According to Malaysia Healthcare Travel Council, the country is expected to host medical facilities for more than one million medical tourist, accounting for revenues of US$ 310.4 million for 2017.

Request A consult-us @ https://www.coherentmarketinsights.com/insight/consult-us/2031

Major players operating in the coronary stents market include Boston Scientific Corporation, Abbott, Medtronic plc, B. Braun Melsungen AG, Stentsy SA, Terumo Interventional Systems, Kyoto Medical Planning Co., Ltd., QualiMed, Elixir Medical Corporation, ENDOCOR GmbH, BIOTRONIK SE & Co. KG, Amaranth Medical, Inc. and Arterial Remodeling Technologies SA

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.